JPRN-UMIN000007559
Recruiting
Phase 2
A randomized phase II trial of adjuvant immunotherapy with alpha-GalactosylCeramide-pulsed dendritic cells for advanced oropharyngeal and hypopharyngeal cancer following standard therapy - A randomized phase II trial of adjuvant immunotherapy with alpha-GalactosylCeramide-pulsed dendritic cells for advanced oropharyngeal and hypopharyngeal cancer following standard therapy
Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University0 sites80 target enrollmentMarch 23, 2012
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Oropharyngeal and Hypopharyngeal squamous cell carcinoma
- Sponsor
- Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who have: uncontrolled diabetes mellitus, pulmonary fibrosis, and/or infection; a history of hepatitis; a positive response for hepatitis B surface antigen, or human immunodeficiency virus (HIV), hepatitis C virus, or human T\-lymphotrophic virus antibodies; serious cardiac disease; recieived concurrent corticosteroid therapy; pregnancy or lactation; autoimmune diseases; been judged to be inappropriate to participate in this study by principle investigator or co\-investigator
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Phase II trial evaluating the immunological and clinical efficay and safety of HER-2 Protein Autovac(TM) monotherapy in patients with metastatic breast cancer - NAFemale patients with histologically proven metastatic or locally advanced breast cancer who have HER-2 overexpression in the primary tumour and/or a metastatic lesion.EUCTR2004-000838-36-HUPharmexa A/S60
Active, not recruiting
Not Applicable
A Phase II trial evaluating the immunological and clinical efficacy and safety of HER-2 Protein AutoVac(TM) and Stimulon® Adjuvant QS-21 monotherapy in patients with metastatic breast cancerEUCTR2005-000558-60-HUPharmexa A/S60
Active, not recruiting
Phase 1
A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients With metastatic hormone receptor positive breast cancerEUCTR2017-000220-10-BEOslo University Hospital75
Completed
Phase 1
A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinomahepatocellular carcinomaJPRN-UMIN000029991Yamaguchi University Graduate School of Medicine20
Completed
Not Applicable
Phase II Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells, Teceleukin, and Zoledronic acid in Patients With Stage IV Renal Cell CarcinomaCytokine refractory Renal cell carcinomaJPRN-UMIN000004482Tokyo Women's Medical University35